Rucaparib Camsylate 200 mg, 250 mg, 300 mg Suppliers & Bulk Manufacturers
Available Forms: Oral tablets
Available Strengths: 200 mg, 250 mg, 300 mg
Reference Brands: Rubraca® (EU & US)
Category: Oncology Cancer Care
Rucaparib Camsylate is a PARP inhibitor used for treating ovarian, fallopian tube, and peritoneal cancers, particularly those with BRCA mutations. Marketed under Rubraca®, it is available in 200 mg, 250 mg, and 300 mg oral tablets. Manufactured in GMP-compliant facilities, Rucaparib offers a targeted approach to cancer treatment and is a reliable choice for pharmaceutical distributors in US and EU markets.
Product Description:
Rucaparib Camsylate is an innovative PARP inhibitor used in the treatment of ovarian, fallopian tube, and peritoneal cancers. This targeted therapy is especially effective in cancers with BRCA mutations, as it disrupts DNA repair mechanisms in cancer cells, leading to their destruction. Available under the brand name Rubraca®, it is offered in 200 mg, 250 mg, and 300 mg oral tablet strengths. Manufactured under GMP-certified conditions, Rucaparib is a trusted solution in oncology care. Ideal for US and EU pharmaceutical distributors and wholesalers, it provides an advanced treatment option in precision medicine for cancer patients.
Rucaparib Camsylate — third party manufacturing & bulk supply
Rucaparib Camsylate 200 mg, 250 mg, 300 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Rucaparib Camsylate is supplied as Oral tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Rucaparib Camsylate listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Rucaparib Camsylate →Frequently Asked Questions
Rucaparib Camsylate is used in the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer, particularly in patients with BRCA-mutated tumors or who have received prior chemotherapy. It works as a targeted therapy to block cancer cell DNA repair, leading to cell death and slowing tumor growth.
Rucaparib Camsylate tablets contain rucaparib camsylate, a PARP (poly ADP-ribose polymerase) inhibitor that prevents DNA repair in cancer cells, inducing apoptosis and controlling tumor progression.
The trade name is Rubraca.
Rucaparib Camsylate is manufactured by Clovis Oncology and distributed globally under the brand Rubraca.
The generic name is rucaparib camsylate.
The brand name is Rubraca.
It is manufactured in the USA and distributed to other regions including the EU, UK, India, and LATAM by Clovis Oncology.
Related Products
Palonosetron Injection
Strength:
0.25 mg/5 mL (0.05 mg/mL)
Form: IV Injection
Reference Brands: Aloxi (US & EU)
View Details
Rituximab
Strength:
IV infusion: 100 mg/10 mL, 500 mg/50 mL; SQ: 1400 mg/11 mL
Form: IV Infusion; Subcutaneous
Reference Brands: Rituxan®(US), MabThera®, Truxima®(EU);Ruxience®(US)
View Details
Epirubicin Hydrochloride
Strength:
10 mg/5 mL, 50 mg/25 mL, 100 mg/50 mL
Form: Injection (IV)
Reference Brands: Ellence® (US) , Farmorubicin®(EU)
View Details
Carbamazepine
Strength:
100 mg, 200 mg, 400 mg; Suspension: 100 mg/5 mL
Form: Oral Tablets and Suspension
Reference Brands: Tegretol®, Tegretol XR®, Carbatrol®, Epitol® (US & EU)
View Details
Entrectinib
Strength:
100 mg, 200 mg
Form: Capsules
Reference Brands: Rozlytrek (USA/EU)
View Details
Imetelstat
Strength:
47 mg, 188 mg
Form: Injection
Reference Brands: Generic formulations marketed under different names
View Details
Regorafenib
Strength:
40 mg, 80 mg, 120 mg, 160 mg
Form: Tablets
Reference Brands: Stivarga (USA/EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
